4'-Thio-2'-Deoxynucleosides Inhibit Orthopoxvirus Replication
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for orthopoxvirus infections, such as smallpox, lack effective drug therapies, making it difficult to manage outbreaks and bioterrorism-related scenarios, with existing vaccines only being effective in the initial stages of an outbreak.
Innovation Solution
Development of specific pyrimidine nucleosides, represented by compounds like 5-iodo-4′-thio-2′-deoxyuridine, which can be administered to inhibit orthopoxvirus infections by targeting the virus directly and providing effective treatment options beyond vaccination.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If vaccines are used to prevent orthopoxvirus infections, then immunity can be provided in the initial stages of an outbreak, but there is no approved drug treatment available for later stages or immunocompromised patients
Solution Approach 1:
The patent modifies the chemical structure of nucleosides by introducing a sulfur atom at the 4' position and various substituents at the 5 position (such as iodo, alkyl, aryl groups) to create compounds with enhanced antiviral activity against orthopoxviruses. These structural parameter changes enable the compounds to effectively inhibit viral replication while being usable as treatment options beyond what vaccines provide
Solution Approach 2:
The patent uses acyclic sugar nucleoside analogs as intermediary compounds that mimic natural nucleosides but contain modified sugar moieties (with sulfur substitution at the 4' position). These intermediary structures allow the compounds to be recognized and incorporated by viral polymerases, thereby inhibiting viral DNA synthesis without being recognized by host cell repair mechanisms
2Difficulty of detecting and measuring
If smallpox has not occurred for two decades, then diagnosis would be very difficult in a major outbreak, but the disease has high morbidity and about 30% mortality
Solution Approach 1:
The patent develops antiviral compounds that can be stockpiled and deployed immediately upon detection of orthopoxvirus outbreaks. The compounds are designed to be effective against multiple orthopoxvirus strains including variola, providing a ready-to-use treatment option that addresses the high mortality risk while diagnosis is being established
3Reliability
If compounds with high antiviral activity are developed, then complete protection from mortality is achieved in animal models, but the complexity of compound synthesis and characterization increases
Solution Approach 1:
The patent divides the nucleoside molecule into distinct functional segments: a modified sugar portion (with 4' sulfur substitution and various hydroxyl/ether configurations), a nitrogenous base (pyrimidine or purine), and optional 5-position substituents. This segmentation allows for modular synthesis where each component can be prepared and characterized separately, then combined to create the final antiviral compound
Solution Approach 2:
The patent systematically varies specific parameters of the nucleoside structure (sugar configuration, sulfur substitution position, base type, 5-position substituents) to optimize antiviral activity while maintaining tractable synthesis routes. The acyclic sugar configuration and 4' sulfur substitution are key parameter changes that distinguish these compounds while enabling their preparation through established organic synthesis methods
Data Source
AI summary
Compound represented by the formulae:wherein each R individually is H or aliphatic acyl or aromatic acyl group; X is selected from the group consisting of hydrogen, fluoro, chloro, bromo, iodo, alkoxy, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, amino, monoalkylamino, dialkylamino, cyano, aryl and nitro; pharmaceutically acceptable salts thereof, prodrugs thereof and mixtures thereof are used as inhibitors of orthopoxviruses and for treating patients suffering from an orthopoxvirus infection such as, but not limited to, smallpox, cowpox, monkeypox and camelpox.